Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies

NCT03126110 is registered in ClinicalTrials.gov with Incyte Biosciences International Sàrl as lead sponsor.

NCT NCT03126110
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03126110 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
Lead sponsor
Incyte Biosciences International Sàrl
Phase
Phase 1/2
Overall status
Completed
Start date
April 25, 2017
Completion date
November 9, 2021
Enrollment
145 (actual)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignancies, metastatic cancer